ProfileGDS5678 / 1440890_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 83% 83% 85% 84% 87% 85% 83% 86% 81% 82% 85% 83% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.01883
GSM967853U87-EV human glioblastoma xenograft - Control 26.1263983
GSM967854U87-EV human glioblastoma xenograft - Control 36.1145783
GSM967855U87-EV human glioblastoma xenograft - Control 46.6059285
GSM967856U87-EV human glioblastoma xenograft - Control 56.2640784
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4021287
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1892385
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0761783
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5009386
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8767481
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9107682
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4531485
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.108483
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3360385